Clinical trials: E.Coli Infections
Hemolytic Uremic Syndrome
Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome
OBJECTIVES: I. Determine the effect of SYNSORB Pk therapy on mortality and frequency of severe extrarenal complications observed in children with acute stage E. coli-associated hemolytic uremic syndrome. II.
- Trial name
- NCT00004465
- Testing
- SYNSORB Pk
- Where
- 27 sites in United States, Canada
- Volunteers
- 145 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Extended Spectrum Beta Lactamases (ESBL) E. Coli
Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli
This study is to identify and isolate well-defined microbials (non-ESBL E. coli) in an observational setting exploring natural gastrointestinal decolonization of humans colonized with ESBL E. coli.
- Trial name
- NCT04764500
- Testing
- examination of stool sample, patient questionnaire, examination of blood sample
- Where
- Switzerland
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Escherichia Coli Diarrhea
Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh
The purpose of this study is to determine if the ETEC vaccine ETVAX with and without dmLT adjuvant is safe and immunogenic in adults, children, toddlers and infants in Bangladesh.
- Trial name
- ETVAX/dmLT (NCT02531802)
- Testing
- ETVAX, dmLT, Bicarbonate Buffer
- Where
- Bangladesh
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- PATH
Infection, Achlorhydria
Clinical Experiment of Helicobacter Pylori Transmission
The study proposes to test whether chronic infection with Helicobacter pylori protects individuals from symptomatic infection with enteropathogenic E. coli.
- Trial name
- NCT00550368
- Testing
- Biological intervention: Enteropathogenic E. coli
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Stanford University
Staphylococcus Aureus Infection
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
Before this study, there will be an open-label, dose-escalation pilot study with a total of 30 participants with 10 per dosage group.
- Trial name
- NCT02804711
- Testing
- Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml), Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml), High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
HIV, Malaria
Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance
At least three studies in sub-Saharan Africa have demonstrated a decrease in morbidity or mortality among HIV-infected adults who took daily cotrimoxazole (trimethoprim sulfamethoxazole) [CTX] prophylaxis.
- Conditions
- HIV, Malaria, Diarrhea, Pneumonia
- Trial name
- NCT00137657
- Testing
- Cotrimoxazole (trimethoprim sulfamethoxazole)
- Where
- Kenya
- Volunteers
- 1,478 people
- Sponsor
- Centers for Disease Control and Prevention
Bacterial Infection
Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy
The purpose of this study is to discover how often certain bacteria are found in the rectum at the time of a prostate needle biopsy to diagnose prostate cancer.
- Trial name
- NCT00915213
- Where
- 3 sites in United States
- Volunteers
- 136 people
- Sponsor
- University of California, Irvine
Hepatitis E
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)
This phase IV clinical study was designed to evaluate the safety and immunogenicity of the recombinant Hepatitis E vaccine(Hecolin®), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged over 65 years of…
- Trial name
- NCT02417597
- Testing
- Recombinant Hepatitis E Vaccine (Escherichia Coli)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Infection, E Coli Infections
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
The purpose of this study is to review patients with E. coli infections at the University of Pittsburgh Medical Center (UPMC) from September 1, 2006 to August 31, 2007 to determine if these infections have arisen in the community…
- Conditions
- Infection, E Coli Infections, Klebsiella Infections, Proteus Infections
- Trial name
- NCT00363220
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Pittsburgh
Recurrent Urinary Tract Infections
Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment
Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. It affects 150 million people annually. Treatment of patients with UTI entails a high consumption of antibiotics and large social and health…
- Trial name
- BIrUTI (NCT04846803)
- Testing
- ABU bladder lavage, Saline bladder lavage
- Where
- 2 sites in Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Condylomata Acuminata
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
This phase I clinical study was designed to evaluate the safety and immunogenicity of the novel recombinant HPV type 6/11 bivalent vaccine, manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged over 18-55…
- Trial name
- NCT02405520
- Testing
- low dosage HPV Vaccine, medium dosage HPV Vaccine, high dosage HPV Vaccine
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Diarrhea
Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.
The primary objective of this study is to assess the safety and tolerability of rifaximin 600 mg (3 x 200-mg tablets) once daily compared with placebo when taken for 14 days by healthy subjects to prevent travelers' diarrhea (TD)…
- Trial name
- NCT00328380
- Testing
- Rifaximin
- Where
- 3 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Polio
Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults
In this study, the safety and tolerability of inactivated polio vaccine (IPV) co-administered with dmLT will be assessed, as well as whether co-administration of dmLT with IPV enhances mucosal responses compared to those with IPV…
- Trial name
- NCT04232943
- Testing
- Inactivated Poliomyelitis Vaccine (IPV), E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant), Bivalent Oral Polio Vaccine (bOPV)
- Where
- Belgium
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- PATH
Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease
A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS
Hemolytic Uremic Syndrome (HUS) is a foodborne disease which mainly affects children. It is caused by Escherichia coli bacteria, which release a toxin called Shiga toxin within the body.
- Conditions
- Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease, Hemolytic-Uremic Syndrome
- Trial name
- NCT05569746
- Testing
- INM004, SoC
- Where
- 16 sites in Argentina
- Volunteers
- 57 people
- Sponsor
- Inmunova S.A.
Acute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli
Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli
Escherichia coli is the primary cause of urinary tract infections and Gram-negative bacteremia worldwide. Since the early years of the 21st century, E.coli has acquired a new mechanism of resistance to antibiotics: extended…
- Trial name
- FOXICOLI (NCT01820793)
- Testing
- Cefoxitin
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bloodstream Infection, Sepsis
Granzyme A in Patients With E. Coli Bacteremic Urinary Tract Infections
Background: Survival in Granzyme A gene (gzmA) knocked-out mice was significantly longer than in wild-type mice in a murine peritonitis model (cecal ligation puncture).
- Conditions
- Bloodstream Infection, Sepsis, Pathogenesis, Escherichia Coli Bacteremia
- Trial name
- GABEC (NCT03991793)
- Volunteers
- 50 people
- Sponsor
- Instituto de Investigación Sanitaria Aragón
Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles Mumps and Rubella Combined Vaccine, Live（MMR）
- Conditions
- Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Measles, Rubella
- Trial name
- NCT05279248
- Testing
- HPV+MMR（0d），HPV（6m）, HPV（0d），HPV（6m），MMR（7m）, MMR（0d），HPV（1m），HPV（7m）
- Where
- 2 sites in China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Hepatitis E
Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）
The purpose of this study is to determine the safety and immunogenicity of the recombinant hepatitis E vaccine in people older than 65 years, and evaluate the efficacy of hepatitis E vaccine in this population.
- Trial name
- NCT02189603
- Testing
- Recombinant (E. Coli) Hepatitis E Vaccine
- Where
- China
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Bloodstream Infections
RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.
No randomized controlled trials (RCTs) have yet been performed comparing different treatment options for AmpC or ESBL-producing Enterobacteriaceae.
- Trial name
- MERINO (NCT02176122)
- Testing
- Meropenem, Piperacillin-tazobactam combination product
- Where
- 31 sites in Australia, Canada and 7 more
- Volunteers
- 391 people
- Sponsor
- The University of Queensland
Antibiotic Resistance, Enterobacteriaceae Infections
Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France
Carbapenemase-producing Enterobacteriaceae (CPE) are classified as emerging Highly Resistant Bacteria (eHRB) because they expose infected patients to the risk of treatment failure due to the strains' resistance to last-line…
- Conditions
- Antibiotic Resistance, Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection, Colonization
- Trial name
- CARBACOLI (NCT07676513)
- Testing
- MultiLocus Sequence Typing
- Where
- France
- Volunteers
- 163 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes